Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

doi:10.1056/NEJMoa1801946

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

The New England journal of medicine - 31 May 2018

Hellmann Matthew D, Ciuleanu Tudor-Eliade, Pluzanski Adam, Lee Jong Seok, Otterson Gregory A, Audigier-Valette Clarisse, Minenza Elisa, Linardou Helena, Burgers Sjaak, Salman Pamela, Borghaei Hossein, Ramalingam Suresh S, Brahmer Julie, Reck Martin, O'Byrne Kenneth J, Geese William J, Green George, Chang Han, Szustakowski Joseph, Bhagavatheeswaran Prabhu, Healey Diane, Fu Yali, Nathan Faith, Paz-Ares Luis

Abstract excerpt

BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Antineoplastic Combined Chemotherapy Protocols

Share to B7-H1 Antigen

Share to Disease-Free Survival

Share to Ipilimumab

Share to Kaplan-Meier Estimate

Share to Nivolumab

Source

Open in PubMed Open full text

Identifiers

PMID: 29658845
DOI: 10.1056/NEJMoa1801946
PMCID: PMC7193684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.PMID 29658845Read ↗

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.Semantic proximity Read ↗

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Semantic proximity Read ↗

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis.Semantic proximity Read ↗

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Semantic proximity Read ↗

The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis.Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer.Semantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

Higher Tumor Mutation Burden Was a Predictor for Better Outcome for NSCLC Patients Treated with PD-1 Antibodies: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read ↗

The emerging development of tumor mutational burden in patients with NSCLC.Semantic proximity Read ↗

Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.